Naloxone is a drug that effectively reverses an opioid overdose. It is an antagonist to opioids. This indicates that it binds to opioid receptors, where it blocks and reverses the effects of other opioids. If someone's respiration has slowed down or halted due to an opioid overdose, naloxone can swiftly get them back to normal breathing.
However, naloxone has no impact on people who do not have opioids in their system, and it is not used to treat opioid use disorder. Opioids include heroin, fentanyl, oxycodone (OxyContin), hydrocodone (Vicodin), codeine, and morphine.
Global Naloxone Market- Impact of Coronavirus (Covid-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Dashboard by the World Health Organization, over 545 million cases and 6.33 million deaths due to coronavirus disease (COVID-19) were reported till July 01, 2022, across the globe.
Impact of COVID-19 on Demand and Supply of Naloxone
Figure 1: Global Naloxone Market Share (%) Analysis, By Strength, 2022
Increasing dependency on drugs and opioids overdose is expected to drive growth of the global naloxone market over the forecast period.
For instance, according to the data published by World Health Organization in August 2021, around 0.5 million deaths are caused by drug use, with more than 30% of these deaths attributable to overdose and more than 70% of these deaths caused due to opioids worldwide. Moreover, according to the data published by the Centers for Disease Control and Prevention, 2021, the national public health agency of the U.S. in November 2021, around 100,306 drug overdose deaths were reported in U.S. during 12-month period ending in April 2021.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 1,118.3 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 10.4% | 2030 Value Projection: | US$ 2,460.2 Mn |
| Geographies covered : |
|
||
| Segments covered: |
|
||
| Companies covered : |
Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Increasing Initiatives by Government and Private Organizations
Various naloxone manufacturers, private organizations, and government organizations are focusing on initiatives to reduce death rate related to opioids overdose by increasing access to products such as naloxone for the population. For instance, on March 3, 2022, the Delaware Department of Health and Social Services’ Division of Substance Abuse and Mental Health (DSAMH) announced about hosting free monthly naloxone access training for all members of the Delaware state. This training will include learning about recognizing and responding to an opioid overdose.
Global Naloxone Market- Restraint
Low awareness and accessibility of naloxone is expected to be major restrain for the market growth. For instance, according to data published by the European Monitoring Centre for Drugs and Drug Addiction in 2016, naloxone was available in only a third of EU (European Union) member states, despite it being listed as an essential medicine by the WHO. Hence, low accessibility of naloxone among such key regions is expected to be a major restrain for the market growth.
Global Naloxone Market – Regional Analysis
On the basis of region, the global naloxone market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to exhibit lucrative growth opportunities for the naloxone market, owing to increasing product launches or approvals by market players in U.S. For instance, in April 2021, Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, announced the approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg, by the U.S. Food and Drug Administration (FDA) for the emergency treatment of known or suspected opioid overdose, as exhibited by respiratory and/or central nervous system depression, for adult and pediatric patients.
Moreover, Asia Pacific is expected to witness significant growth in the near future, owing to increasing government initiatives for naloxone distribution in the region. For instance, in February 2022, the Australian Government invested US$ 3.9 million in the ‘take home naloxone pilot’, a program to make naloxone available free to people who may experience, or witness, an opioid overdose.
Figure 2: Global Naloxone Market Value (US$ Mn), by Region, 2022
Global Naloxone Market – Competitive Landscape
Major players operating in the global naloxone market include Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc.
Naloxone is available in two U.S. Food and Drug Administration (FDA) approved forms: injection and nasal spray. It is crucial to be educated on how and when to administer naloxone regardless of the type of medication being utilized. Those who are physically dependent on opioids may experience withdrawal symptoms minutes after receiving naloxone. Headaches, variations in blood pressure, a rapid heartbeat, sweating, nausea, vomiting, and tremors are examples of withdrawal symptoms. Although uncomfortable, this normally does not pose a life-threatening threat.
Market Dynamics
High prevalence of opioid overdose and increasing opioid crises in the U.S. are expected to fuel demand for naloxone in the region and thus, driving the market growth during the forecast period. For instance, according to the data published by the National Institute on Drug Abuse, 2021, U.S. federal government research institute, in the year 2019, about 50,000 people died from opioid-involved overdoses in the U.S. The addiction and misuse of opioids including heroin, synthetic opioids (fentanyl), and prescription pain relievers is a severe national crisis which affects social & economic welfare, and public health.
Market players are focused on product launches and approvals, which is expected to drive growth of the global naloxone market over the forecast period. For instance, in February 2019, Indivior Inc., a U.S. affiliate of Indivior Plc., launched an authorized generic version of SUBOXONE (naloxone and buprenorphine) sublingual film in the U.S. This authorized generic is being distributed and marketed on Indivior’s behalf by Sandoz Inc., one of the leading providers of generic pharmaceuticals and biosimilars.
Increasing initiatives by governments related to use and distribution of naloxone is expected to fuel growth of the global naloxone market. For instance, in February 2018, Loyola Medicine and the U.S. based Cook County Department of Homeland Security and Emergency Management collaborated, where Loyola Medicine trained police to use Narcan in the case of opioids overdose. Moreover, in 2017, Ontario government provided naloxone kits to police and fire departments in Ontario, Canada, to manage emergency case of opioid overdose. Government of Canada offered naloxone kits to all 61 police services and 447 fire departments in the Ontario province.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients